Open AccessCost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain
Author(s) -
María Mareque,
Pau Montesinos,
Patricia Font,
José María Guinea de Castro,
Adolfo de la Fuente,
Javier Soto,
Itziar Oyagüez,
James Brockbank,
Tamara Iglesias,
Julia Llinares,
Jorge Sierra
Publication year - 2021
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s302097
Subject(s) - gemtuzumab ozogamicin , medicine , cohort , quality adjusted life year , adverse effect , cost–utility analysis , oncology , cost effectiveness , intensive care medicine , stem cell , cd34 , risk analysis (engineering) , genetics , cd33 , biology